Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 16/20 | 0.70 |
| ▸ | CA1 | P00915 | 15/20 | 0.62 |
| ▸ | CA2 | P00918 | 15/20 | 0.62 |
| ▸ | CA12 | O43570 | 7/20 | 0.62 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.60 |
| ▸ | CA7 | P43166 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALPL | P05186 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALPI | P09923 | 1/20 | 0.51 |
| ▸ | ALPG | P10696 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915130 | 0.92 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17898063 | 0.92 | CA9 (0.59) | CA9CA1CA2CA12CA14 | |
| SCHEMBL10035691 | 0.90 | CA9 (0.65) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17522975 | 0.89 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18163373 | 0.89 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL16521412 | 0.88 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL17522977 | 0.88 | CA9 (0.64) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18559017 | 0.87 | CA9 (0.60) | CA9CA1CA2CA12CA14 | |
| SCHEMBL20115479 | 0.87 | CA9 (0.68) | CA9CA1CA2CA12CA14 | |
| SCHEMBL15130552 | 0.86 | USP2 (0.62) | CA9CA1CA2CA12USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210162058-A1 | ENGINEERED POLYPEPTIDE CONJUGATES USING TRANSGLUTAMINASE | RINAT NEUROSCIENCE CORP. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10941216-B2 | Engineered polypeptide conjugates and methods for making thereof using transglutaminase | PFIZER INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-10842881-B2 | Engineered polypeptide conjugates using transglutaminase | RINAT NEUROSCIENCE CORP. (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190321482-A1 | ENGINEERED POLYPEPTIDE CONJUGATES USING TRANSGLUTAMINASE | RINAT NEUROSCIENCE CORP. (US) | 2019-10-24 | — | — | US | disclosed |
| US-10195289-B2 | Engineered polypeptide conjugates using transglutaminase | RINAT NEUROSCIENCE CORP. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20170313787-A1 | ENGINEERED POLYPEPTIDE CONJUGATES AND METHODS FOR MAKING THEREOF USING TRANSGLUTAMINASE | PFIZER INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-9676871-B2 | Engineered polypeptide conjugates and methods for making thereof using transglutaminase | PFIZER INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170043033-A1 | ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | RINAT NEUROSCIENCE CORP. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10195289-B2 | Engineered polypeptide conjugates using transglutaminase | TGM2, TGM3, TGM1 | CA9 1591/4885CA1 2150/4885CA2 3064/4885 |
| US-10842881-B2 | Engineered polypeptide conjugates using transglutaminase | TGM2, TGM3, TGM1 | CA9 1591/4885CA1 2150/4885CA2 3064/4885 |
| US-20190321482-A1 | ENGINEERED POLYPEPTIDE CONJUGATES USING TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | CA9 1591/4885CA1 2150/4885CA2 3064/4885 |
| US-20210162058-A1 | ENGINEERED POLYPEPTIDE CONJUGATES USING TRANSGLUTAMINASE | TGM2, TGM3, TGM1 | CA9 1591/4885CA1 2150/4885CA2 3064/4885 |
| US-20170043033-A1 | ANTIBODY-DRUG CONJUGATES WITH HIGH DRUG LOADING | GATD3, GLUL, SLC7A11 | CA9 1689/4885CA1 2104/4885CA2 3235/4885 |
| US-20170313787-A1 | ENGINEERED POLYPEPTIDE CONJUGATES AND METHODS FOR MAKING THEREOF USING TRANSGLUTAMINASE | QPCT, QPCTL, TGM3 | CA9 1046/4885CA1 1547/4885CA2 2460/4885 |
| US-10941216-B2 | Engineered polypeptide conjugates and methods for making thereof using transglutaminase | QPCT, QPCTL, TGM3 | CA9 1046/4885CA1 1547/4885CA2 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.